Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. [More]
BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform. [More]
Asthma Ally app allows patients to connect with allergist's office for assistance

Asthma Ally app allows patients to connect with allergist's office for assistance

The adage, "There's an app for that" is even more true in light of an app that sends an alert to your allergist's office when your asthma may be out of control. [More]

Immunotherapy for kidney cancer - Phase 3 update from Argos Therapeutics at ASCO

Argos is developing AGS-003, which is a fully personalized immunotherapy designed to induce a durable memory T-cell response specific to each patient’s cancer... [More]
Regulatory T cells can cure inflammatory diseases, shows research

Regulatory T cells can cure inflammatory diseases, shows research

Scientists at The University of Manchester have made an important discovery about an immune cell which is already being used in immunotherapy to treat diseases such as type I diabetes. [More]
Researchers devise novel method to perform NIR optical measurements of resected breast tissue

Researchers devise novel method to perform NIR optical measurements of resected breast tissue

Roughly 1 in 4 women having breast conserving surgery (BCS) return to the surgical suite for further resection because of cancerous tissue left behind due to unclear margins. Investigators at the Optics in Medicine Lab at Dartmouth's Thayer School of Engineering and Norris Cotton Cancer Center, led by Brian W. Pogue, PhD and Keith Paulsen PhD, with first author and PhD candidate David M. McClatchy III, devised a novel approach to perform near infrared (NIR) optical measurements of resected breast tissue after the margins have had their traditional marking by the surgeon to preserve information about their orientation for potential follow-up surgeries. [More]
Research paves way for development of individualized immunotherapy for treating cancer

Research paves way for development of individualized immunotherapy for treating cancer

Mainz-based researchers have made significant advances with regard to the development of individualized immunotherapy strategies for treating cancer. They have managed to identify the relevant genetic changes or mutations associated with various types of cancer and have determined their individual blueprints. [More]
Invectys begins INVAC-1 phase I clinical trial in cancer patients

Invectys begins INVAC-1 phase I clinical trial in cancer patients

Invectys announces today that it has initiated a phase I clinical trial of its immunotherapeutic drug candidate INVAC-1. [More]
Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Understanding how to overrule a signaling pathway that can cause treatments to fail in metastatic melanoma patients should help physicians extend the benefits of recently approved immunity-boosting drugs known as checkpoint inhibitors to more patients. [More]
Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia (ALL). Led by Memorial Sloan Kettering Cancer Center, the trial is one of several nationally that are evaluating cancer immunotherapy, a treatment approach -- hailed by Science magazine as their Breakthrough of the Year in 2013 -- that triggers a patient's immune system to attack his or her cancer cells. [More]
Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers. [More]
Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Heather Wakelee, MD, is the recipient of the 2015 ECOG-ACRIN Young Investigator Award, the ECOG-ACRIN Cancer Research Group announced today. Dr. Wakelee is associate professor of medicine in the Division of Oncology at the Stanford University School of Medicine in Stanford, Calif. [More]
NanoPass signs license agreement for supply of MicronJet600 device to Circassia

NanoPass signs license agreement for supply of MicronJet600 device to Circassia

NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for the supply of MicronJet600, its microneedle delivery device, to Circassia Pharmaceuticals plc. (Oxford, UK), a specialty biopharmaceutical company focused on the allergy market. [More]
Antigen-loaded porous silicon microparticles can boost effectiveness of breast cancer vaccines

Antigen-loaded porous silicon microparticles can boost effectiveness of breast cancer vaccines

The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online). [More]
Study: Women hospitalized for asthma treatment more than men

Study: Women hospitalized for asthma treatment more than men

While it may be a stereotype, it's also true that women seek medical care more frequently than men do. And a recent study shows that women with acute asthma who are treated in the emergency department (ED) are 60 percent more likely than men treated in the ED to need hospitalization. [More]

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that activity and tolerance data for its second lead product Col-Treg were presented through a poster presentation at the 2015 ARVO Annual Meeting, May 3-7, 2015, in Denver, Colorado, US. [More]
Keynote 24 study explores investigational approach to treating lung cancer

Keynote 24 study explores investigational approach to treating lung cancer

Lung cancer impacts the lives of millions of people worldwide. In nearly 40 percent of people diagnosed with lung cancer, it has metastasized, or spread to other areas of the body, making it difficult to treat. Immunotherapy is a type of therapy that uses the body's own immune system to help fight cancer. Immunotherapy may help the body's immune system target cancer cells. [More]
Novel combination therapy shows promise in mouse models of advanced prostate cancer

Novel combination therapy shows promise in mouse models of advanced prostate cancer

Chemotherapy can be very effective against small prostate tumors. Larger prostate tumors, however, accumulate cells that suppress the body's immune response, allowing the cancer to grow despite treatment. [More]
Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences, Inc. announced that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics will be presented at the 18th Annual Meeting of the American Society of Gene and Cell Therapy [More]
Oncologists publish review of advanced clinical treatments for pancreatic cancer

Oncologists publish review of advanced clinical treatments for pancreatic cancer

The oncologists Manuel Hidalgo, Director of the Clinical Research Programme of the Spanish National Cancer Research Centre, and Ignacio Garrido-Laguna, member of the Experimental Therapeutics Program at Huntsman Cancer Institute of the University of Utah (USA), have recently published a review of state-of-the-art clinical treatments for pancreatic cancer -- including the most current therapies and innovative research -- in the prestigious scientific journal Nature Reviews Clinical Oncology. [More]
Advertisement
Advertisement